Revolutionizing HIV Management with Long-Acting Injectables

At the International AIDS Society 2025 Conference in Kigali, Rwanda, ViiV Healthcare has revealed groundbreaking data showcasing the effectiveness of its innovative long-acting injectables for HIV treatment and prevention. The presentation focuses on the combination of Vocabria and Rekambys (cabotegravir + rilpivirine LA), which signifies a new era in HIV care.

Promising Phase IIIb Results on Patient Choices

New phase IIIb data highlights the preferences of treatment-naive adults who reached rapid viral suppression with daily oral therapy Dovato (DTG/3TC) and were then offered the option to switch to the long-acting injectable regimen.

Real-World Insights Amplified

Interim findings from the Positive Perspectives study reveal that joint decision-making between patients and providers significantly boosts satisfaction and health outcomes in HIV treatment. Jean van Wyk, Chief Medical Officer at ViiV Healthcare, stated, “Our robust real-world insights affirm that long-acting injectables are reshaping HIV management, meeting the diverse needs of affected individuals and offering them greater flexibility.”

Key Data Highlights from IAS 2025

ViiV Healthcare’s presentation will spotlight several crucial aspects of their HIV treatment portfolio, including:

1. **Patient Preferences**: New data from the phase IIIb VOLITION study unveils how ART-naive adults prefer the CAB+RPV LA option post-viral suppression.

2. **Broad Effectiveness Data**: ViiV will present outcomes from multiple real-world studies showing the efficacy and satisfaction tied to CAB+RPV LA across diverse populations.

3. **CAB LA for PrEP Insights**: Implementation studies will shed light on the benefits of Apretude (cabotegravir LA) for pre-exposure prophylaxis, particularly among high-risk groups.

4. **Innovative Treatment Comparisons**: New efficacy data for DTG/3TC and its performance in various demographics will be shared, signaling exciting developments in treatment approaches.

Community Voices Matter

The Positive Perspectives study results will underscore the importance of considering community input in treatment satisfaction and health outcomes. Findings indicate that enhancing awareness about the ‘Undetectable = Untransmittable (U=U)’ campaign remains vital for empowering those living with HIV.

A Commitment to Evolving HIV Care

As ViiV Healthcare prepares for a pivotal presentation at IAS 2025, the emphasis remains on delivering safe, effective, and user-friendly therapies to revolutionize HIV care. This commitment reflects a profound understanding of the evolving landscape of HIV treatment, aiming to free patients from the burden of daily medication.

Stay tuned for the crucial findings set to reshape the future of HIV treatment and prevention, empowering individuals across the globe.